Trilostane treatment for pituitary-dependant hyperadrenocorticism in dogs
There are many common variables used to monitor trilostane treatment of dogs with pituitary-dependent hyperadrenocorticism (PDH). However, no one has consistently discriminated dogs receiving an adequate dose (A) from those overdosed (O) or underdosed (U) with.
The goal of this study was to assess and compare recommended monitoring variables in a cohort of dogs with PDH treated with trilostane. This prospective two-day cohort study used twenty-two privately owned dogs with pituitary-dependant hyperadrenocorticism (n = 22) and three healthy dogs (controls).
On the first study day, urine collected at home was assessed for urine specific gravity, urine cortisol : creatinine ratios, and owner opinions regarding pituitary-dependant hyperadrenocortisicm, were categorized as: A (clinical signs resolved), U (remains symptomatic), or ill (possible O).
Using twenty-seven pairs of evaluations, seven dogs were categorized as resolved, nineteen remained symptomatic, and 1 possibly ill (excluded from the study). There was overlap in serum cortisol concentration results from the resolved and symptomatic dogs at every time point.
Results of urine specific gravity, urine cortisol : creatinine ratio, and ACTH stimulation did not discriminate resolved from symptomatic dogs. Trilostane suppresses serum cortisol concentration within one hour of administration and its duration of action in most pituitary-dependent hyperadrenocorticism dogs is less than eight hours.
No single variable or group of variables reliably differentiated resolved dogs from asmyptomatic dogs during trilostane treatment for pituitary-dependent hyperadrenocorticism.
Read more on this article below:
Trilostane treatment for pituitary-dependant hyperadrenocorticism in dogs